4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > MedKoo Biosciences/ARQ-761/205816/50mg
商品详细MedKoo Biosciences/ARQ-761/205816/50mg
MedKoo Biosciences/ARQ-761/205816/50mg
MedKoo Biosciences/ARQ-761/205816/50mg
商品编号: 205816-50mg
品牌: MedKoo
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
ARQ-761isasolubleprodrugofbeta-lapachonewithpotentialantineoplasticandrADIosensitizingactivity.ARQ761isconvertedtobeta-lapachone(b-lap)invivo.Whenb-lapisactivatedbyNAD(P)H:quinoneoxidoreductase-1(NQO1)thisagentcreatesafutileoxidoreduction,generatinghighlyreactiveoxygenspecies(ROS)thatresultsinDNAdamage.Theactivationofb-lapalsocauseshyperactivationofpoly(ADP-ribose)polymerase-1(PARP-1),anenzymethatfacilitatesDNArepair,accompaniedbyrapiddepletionofNAD+/ATPnucleotidelevels.

MedKooCat#:205816
Name:ARQ-761
CAS#:NONE
ChemicalFormula:
ExactMass:
MolecularWeight:
ElementalAnalysis:


Synonym:ARQ761;ARQ-761;ARQ761.

IUPAC/ChemicalName:NONE


TechnicalData

Appearance:
Solidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

  
 
 
 


References

 1:SezaiA,NakataK,IidaM,YoshitakeI,WakuiS,OsakaS,KimuraH,TakahashiK,IshiY,YaoitaH,ArimotoM,HataH,ShionoM,TakayamaT,HirayamaA.AStudyontheOccurrenceandPreventionofPerioperativeStrokeafterCoronaryArteryBypassGrafting.AnnThoracCardiovascSurg.2015Jun25;21(3):275-81.doi:10.5761/atcs.oa.15-00089.Epub2015Jun5.PubMedPMID:26050596.

2:WangLH,DongT,LiuBB,ZhaoXD,ChenJW,MuraoK,ZhuW,ZhangGX.Contributionoftherenin-angiotensinsysteminchronicfoot-shockinducedhypertensioninrats.LifeSci.2015Jan15;121:135-44.doi:10.1016/j.lfs.2014.12.004.Epub2014Dec11.PubMedPMID:25498894.

3:KoboriH,MoriH,MasakiT,NishiyamaA.AngiotensinIIblockadeandrenalprotection.CurrPharmDes.2013;19(17):3033-42.Review.PubMedPMID:23176216;PubMedCentralPMCID:PMC3651580.

4:NishiyamaA,KoboriH,KonishiY,MorikawaT,MaedaI,OkumuraM,KishidaM,HamadaM,NagaiY,NakagawaT,OhashiN,NakanoD,HitomiH,ImanishiM.MineralocorticoidreceptorblockadeenhancestheantiproteinuriceffectofanangiotensinIIblockerthroughinhibitingpodocyteinjuryintype2diabeticrats.JPharmacolExpTher.2010Mar;332(3):1072-80.doi:10.1124/jpet.109.158113.Epub2009Nov25.PubMedPMID:19940106;PubMedCentralPMCID:PMC2835438.

5:ZhangGX,OhmoriK,NagaiY,FujisawaY,NishiyamaA,AbeY,KimuraS.RoleofAT1receptorinisoproterenol-inducedcardiachypertrophyandoxidativestressinmice.JMolCellCardiol.2007Apr;42(4):804-11.Epub2007Feb3.PubMedPMID:17350036.

6:DollarA,BrownC,PutnamD,McLaughlinT,OkamotoL,ArochoR.Aretrospectiveelectronicchartreviewofbloodpressurechangesinelderlypatientstreatedwithamlodipineoranangiotensin-convertingenzymeinhibitororangiotensinIIreceptorblocker.ClinTher.2002Jun;24(6):930-41.PubMedPMID:12117083.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。